Key result
Perioperative etomidate linked to ~35% higher 30-day mortality in hip fracture surgery.
Why the study?
Etomidate is used for anesthetic induction in hemodynamically unstable patients but its transient adrenal suppression raises concern about adverse postoperative outcomes after hip fracture surgery.
Does perioperative etomidate exposure increase 30-day mortality in adult patients undergoing hip fracture surgery?
Cohort (n=12,492)
Yes
Does perioperative etomidate exposure increase 30-day mortality in adult patients undergoing hip fracture surgery?
In older adults undergoing hip fracture surgery, perioperative etomidate exposure is associated with increased short-term mortality, pneumonia, and MACE, suggesting the need for cautious use in this population.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for etomidate risks in hip fracture surgery; prospective trials needed before changing practice.
Etomidate is often used for anesthetic induction in hemodynamically unstable patients because of its cardiovascular stability, but its transient adrenal suppression raises concern about possible adverse postoperative outcomes. We performed a cohort study using the TriNetX Research Network to examine the association between perioperative etomidate exposure and postoperative outcomes in adults undergoing hip fracture surgery. Patients receiving etomidate were matched 1:1 with controls. The primary outcome was 30-day mortality. Secondary outcomes included pneumonia, sepsis, venous thromboembolism, major adverse cardiovascular events (MACEs), and acute kidney injury (AKI). After matching, 6,246 patients were included in each group with balanced baseline characteristics. Etomidate exposure was associated with higher risks of 30-day mortality (OR 1.35, 95% CI 1.15–1.60; P < 0.001), pneumonia (OR 1.23, 95% CI 1.03–1.47, P = 0.019), and MACEs (OR 1.20, 95% CI 1.04–1.40, P = 0.014), but a lower risk of AKI (OR 0.83, 95% CI 0.71–0.96, P = 0.014). No significant associations were observed for sepsis or venous thromboembolism. All associations attenuated and became non-significant during extended follow-up (30–180 day). In conclusion, perioperative etomidate exposure was associated with worse short-term postoperative outcomes except for a lower AKI risk. These findings warrant prospective confirmation.
No takes yet. Share an insight, caveat, or question.
Hung et al. (2026) conducted a cohort in Hip fracture (n=12,492). Perioperative etomidate vs. General anesthesia without documented etomidate exposure was evaluated on 30-day postoperative mortality (OR 1.35, 95% CI 1.15-1.60, p=< 0.001). Perioperative etomidate exposure was associated with a 35% higher risk of 30-day mortality compared to non-etomidate general anesthesia in adults undergoing hip fracture surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: